US inflation data came slightly lower than expected and confirms the Fed thesis that inflation is transitory. The positive response of Dow and S&P to the inflation numbers and the decline in the Dollar index will strengthen the bulls, said an analyst.
Russian COVID-19 vaccine Sputnik V s rollout pushed by another two weeks
Launched in the country as a pilot on May 14, Sputnik V was expected to be rolled out in mid-June, which has now been pushed back by another two weeks Around three million doses of Sputnik V have arrived in India, whereas, the consignment of the second dose is likely to land by the end of this month BusinessToday.In
Updated Jun 26, 2021, 1:35 PM IST
Russia s COVID-19 vaccine, Sputnik V, is yet to be commercially available in India, in view of delays in the import of consignments.
Launched in the country as a pilot on May 14, Sputnik V was expected to be rolled out in mid-June, which has now been pushed back by another two weeks.
Dr Reddy s lines up Rs 1,000 crore capex for current fiscal year
SECTIONS
Last Updated: May 24, 2021, 01:04 PM IST
Share
Agencies
The company remains positive about sustaining its growth trends in the current fiscal and beyond, as per a top company official.
INSIGHTS
NSE
Explore Now
NEW DELHI: Drug major Dr Reddy s Laboratories has earmarked a Capex of around Rs 1,000 crore for the current fiscal as it remains positive about sustaining its growth trends in the current fiscal and beyond, as per a top company official.
The Hyderabad based firm invested about Rs 1,000 crore in the 2020-21 fiscal. The Capex will be around the same numbers, maybe a bit higher if everything goes through, Dr Reddy s Laboratories CEO Erez Israeli said in an analyst call.
Updated:
Developed with DRL, it reduces oxygen-dependence in patients
Share Article
AAA
Defence Minister Rajnath Singh hands over the first batch of 2-DG anti Covid drug to the Union Health Minister Harsh Vardhan, in New Delhi on May 17, 2021. Photo: Twitter/@rajnathsingh
Developed with DRL, it reduces oxygen-dependence in patients
The first batch of the adjunct COVID therapy drug, 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisation (DRDO) along with Dr Reddy’s Laboratories (DRL), Hyderabad was on Monday released for emergency use. Defence Minister Rajnath Singh formally handed over the drug to Health Minister Dr Harsh Vardhan.
“One box each of the sachets of the drug were handed over to Dr. Randeep Guleria, Director All India Institute of Medical Sciences (AIIMS) and Lt. Gen. Sunil Kant of Armed Forces Medical Services (AFMS). More will be handed over to different hospitals across the country for emergency use,” a Defence M